Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis
Margreet Kloppenburg, Charles Peterfy, Ida K Haugen, Féline Kroon, Su Chen, Li Wang, Wei Liu, Gwen Levy, Roy M Fleischmann, Francis Berenbaum, Désirée van der Heijde, Prashant Bansal, Ruth Wittoek, Sheng Feng, Yuni Fang, Mary Saltarelli, Jeroen K Medema, Marc C Levesque
Annals of the Rheumatic Diseases Mar 2019, 78 (3) 413-420; DOI: 10.1136/annrheumdis-2018-213336
